Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

$125m Upfront For InnoCare

 
• By Andrew McConaghie and Brian Yang
Biogen
Biogen wants to stay competitive in MS, and sees BTK inhibitors a potentially key to the field's future. • Source: Alamy

More from Business

More from Scrip